| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8410167 | SANOFI AVENTIS US | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of mortality |
Apr, 2029
(5 years from now) | |
| US9107900 | SANOFI AVENTIS US | Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or of morality |
Apr, 2029
(5 years from now) | |
| US8602215 | SANOFI AVENTIS US | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation |
Jun, 2031
(7 years from now) | |
Multaq is owned by Sanofi Aventis Us.
Multaq contains Dronedarone Hydrochloride.
Multaq has a total of 3 drug patents out of which 0 drug patents have expired.
Multaq was authorised for market use on 01 July, 2009.
Multaq is available in tablet;oral dosage forms.
Multaq can be used as reduction in risk of hospitalization in patients with stable nyha class iii heart failure and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals; reduction in risk of hospitalization in patients with coronary heart disease and a history of paroxysmal or persistent af and with one or more risk factors by administration twice a day with morning and evening meals, reduction in risk of hospitalization in patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals; treatment of patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning and evening meals, management of risk of dronedarone/beta-blocker interaction in patients in sinus rythm with a history of paroxysmal or persistent af.
The generics of Multaq are possible to be released after 30 June, 2031.
Drugs and Companies using DRONEDARONE HYDROCHLORIDE ingredient
Market Authorisation Date: 01 July, 2009
Treatment: Reduction in risk of hospitalization in patients with a history of paroxysmal or persistent af without severe heart failure and with one or more risk factors by administration twice a day with morning...
Dosage: TABLET;ORAL
MULTAQ family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic